Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $231.1 million.

  • Abeona Therapeutics' Liabilities and Shareholders Equity rose 91.63% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $685.6 million, marking a year-over-year increase of 74.27%. This contributed to the annual value of $108.9 million for FY2024, which is 70.20% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Liabilities and Shareholders Equity is $231.1 million, which was down 6.15% from $246.2 million recorded in Q2 2025.
  • Abeona Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $246.2 million during Q2 2025, with a 5-year trough of $38.8 million in Q3 2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $113.8 million, with a median of $99.4 million in 2025.
  • As far as peak fluctuations go, Abeona Therapeutics' Liabilities and Shareholders Equity slumped by 67.43% in 2022, and later skyrocketed by 150.24% in 2024.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Liabilities and Shareholders Equity stood at $79.6 million in 2021, then dropped by 19.31% to $64.2 million in 2022, then decreased by 0.33% to $64.0 million in 2023, then skyrocketed by 70.20% to $108.9 million in 2024, then soared by 91.63% to $231.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $231.1 million for Q3 2025, versus $246.2 million for Q2 2025 and $99.4 million for Q1 2025.